Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cannabis Sativa Inc CBDS

Cannabis Sativa, Inc. is engaged in telehealth through its 51% owned subsidiary and the licensing of cannabis-related intellectual property (IP), marketing and branding for cannabis-based products and services, operation of cannabis-related technology services, and ancillary business activities. It operates through various subsidiaries, including PrestoCorp, Inc. (PrestoCorp), Wild Earth Naturals, Inc., Kubby Patent and Licenses Limited Liability Company, Hi Brands, International, Inc., Eden Holdings LLC, and iBudtender, Inc., GK Manufacturing and Packaging, Inc. PrestoCorp offers an online telemedicine platform providing customer access to knowledgeable physicians to obtain a medical marijuana recommendation. PrestoCorp uses video conferencing technology to provide a safe and confidential forum for the doctor patient interview in accordance with state regulations governing issuance of medical marijuana cards. It offers services in California, Nevada, New York, Missouri, and Oklahoma.


OTCQB:CBDS - Post by User

Post by BruceWAy34on Jan 26, 2021 11:12am
117 Views
Post# 32387216

Game-Changing Innovations

Game-Changing InnovationsSponsored Post This news brought a lot ideas for me! This might help you too!

Along the way, some of the companies that could benefit the most are those with potentially game-changing innovations.  these other companies appears to be well-positioned in a medical green leaf market that could grow to around approximately  $32 billion by 2022.
 
These other companies claim to deliver measured amounts of green leaf straight to the systemic bloodstream through the lungs and with a short burst of aerosolized medicine. Check disclaimer on profile and landing page 
<< Previous
Bullboard Posts
Next >>